SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.
(NYSE: BMR) today announced that its board of directors has declared a first
quarter 2009 dividend of $0.335 per share of common stock. The dividend is
equivalent to an annualized dividend of $1.34 per common share.
BioMed also announced that its board of directors has declared a dividend
of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable
Preferred Stock for the period from January 16, 2009 through April 15, 2009.
Both dividends are payable on April 15, 2009 to stockholders of record at
the close of business on March 31, 2009.
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on Providing Real Estate to the Life Science Industry(R). The company's
tenants primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed owns or has interests in 69
properties, representing 112 buildings with approximately 10.4 million
rentable square feet, including approximately 1.4 million square feet of
development in progress. The company also owns undeveloped land parcels
adjacent to existing properties that it estimates can support up to 1.4
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Diego, San
Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have
well-established reputations as centers for scientific research. Additional
information is available at www.biomedrealty.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: general risks affecting
the real estate industry (including, without limitation, the inability to
enter into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions and developments, and the
ability to refinance indebtedness as it comes due; failure to manage
effectively the company's growth and expansion into new markets, or to
complete or integrate acquisitions and developments successfully; risks and
uncertainties affecting property development and construction; risks
associated with downturns in the national and local economies, increases in
interest rates, and volatility in the securities markets; potential liability
for uninsured losses and environmental contamination; risks associated with
the company's potential failure to qualify as a REIT under the Internal
Revenue Code of 1986, as amended, and possible adverse changes in tax and
environmental laws; and risks associated with the company's dependence on key
personnel whose continued service is not guaranteed. For a further list and
description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE: BioMed Realty Trust, Inc.
Director, Corporate Communications of BioMed Realty
Trust, Inc., +1-858-207-5859
Web Site: http://www.biomedrealty.com